

Item 7.01 Regulation FD Disclosure.

On November 29, 2016, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing the initiation of its Phase I clinical trial for utilizing C-CAR011 in treating patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated November 29, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,
Inc.

Date: November 29, 2016 By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Financial Officer